Literature DB >> 23829281

Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis.

Srdan Verstovsek1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23829281      PMCID： PMC4916492          DOI： 10.3109/10428194.2013.802318

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  8 in total

1.  Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly.

Authors:  Ohad Benjamini; Preetesh Jain; Zeev Estrov; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2012-09-27       Impact factor: 22.113

2.  Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval.

Authors:  Holly Geyer; Keith Cannon; Emily Knight; Veena Fauble; John Camoriano; Robyn Emanuel; Raoul Tibes; Ruben Mesa
Journal:  Leuk Lymphoma       Date:  2013-06-12

3.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

4.  Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.

Authors:  Srdan Verstovsek; Hagop M Kantarjian; Zeev Estrov; Jorge E Cortes; Deborah A Thomas; Tapan Kadia; Sherry Pierce; Elias Jabbour; Gautham Borthakur; Elisa Rumi; Ester Pungolino; Enrica Morra; Domenica Caramazza; Mario Cazzola; Francesco Passamonti
Journal:  Blood       Date:  2012-06-20       Impact factor: 22.113

5.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

Review 6.  Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.

Authors:  Srdan Verstovsek
Journal:  Postgrad Med       Date:  2013-01       Impact factor: 3.840

Review 7.  A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis.

Authors:  John Mascarenhas; Ronald Hoffman
Journal:  Blood       Date:  2013-04-09       Impact factor: 22.113

Review 8.  Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.

Authors:  J Mascarenhas; T I Mughal; S Verstovsek
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530
  8 in total
  1 in total

1.  Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.

Authors:  Francesca Palandri; Giuseppe Alberto Palumbo; Massimiliano Bonifacio; Mario Tiribelli; Giulia Benevolo; Bruno Martino; Elisabetta Abruzzese; Mariella D'Adda; Nicola Polverelli; Micaela Bergamaschi; Alessia Tieghi; Francesco Cavazzini; Adalberto Ibatici; Monica Crugnola; Costanza Bosi; Roberto Latagliata; Ambra Di Veroli; Luigi Scaffidi; Federico de Marchi; Elisa Cerqui; Barbara Anaclerico; Giovanna De Matteis; Marco Spinsanti; Elena Sabattini; Lucia Catani; Franco Aversa; Francesco Di Raimondo; Umberto Vitolo; Roberto Massimo Lemoli; Renato Fanin; Francesco Merli; Domenico Russo; Antonio Cuneo; Maria Letizia Bacchi Reggiani; Michele Cavo; Nicola Vianelli; Massimo Breccia
Journal:  Oncotarget       Date:  2017-06-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.